Podcast by CEO, Norges Bank Investment Management, In Good Company with Nicolai Tangen

In Good Company with Nicolai Tangen

Podcast by CEO, Norges Bank Investment Management

The CEO of the largest single investor in the world, Norges Bank Investment Management, interviews leaders of some of the largest companies in the world. You will get to know the leader, their strategy, leadership principles, and much more. Hosted on Acast. See https://www.acast.com/privacy-policy for more information.

Equity Bottom-Up

<ul><li>The CEO of Novartis, with a medical background, emphasizes the importance of focusing on breakthrough innovations and patient impact in leading the company</li><li>Implemented changes to focus on innovative medicines by spinning off non-core businesses, leading to unlocking significant value for the company</li><li>Novartis structures R&amp;D differently by having a strategy and growth function, focusing on key therapeutic areas, and investing in advanced technology platforms like radio ligand therapies and cell and gene therapies</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>

The CEO of Novartis, with a medical background, emphasizes the importance of focusing on breakthrough innovations and patient impact in leading the companyImplemented changes to focus on innovative medicines by spinning off non-core businesses, leading to unlocking significant value for the companyNovartis structures R&amp;D differently by having a strategy and growth function, focusing on key therapeutic areas, and investing in advanced technology platforms like radio ligand therapies and cell and gene therapiesThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness

Switzerland

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novartis AG Reg (NOVN VX)

Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness

The CEO of Novartis, with a background in medicine and business, has implemented significant changes to focus the company on innovative medicines,...

In Good Company with Nicolai Tangen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)